The unidirectional hypoxia ‐activated prodrug OCT1002 inhibits growth and vascular development in castrate‐resistant prostate tumors

ConclusionsThese studies provide the first evidence that OCT1002 can be an effective agent in treating hypoxic, castrate‐resistant prostate tumors, either singly or in combination with established chemotherapeutics for prostate cancer.

Source: The Prostate - September 25, 2017 Category: Urology & Nephrology Authors: Heather Nesbitt, Jenny Worthington, Rachel J. Errington, Laurence H. Patterson, Paul J. Smith, Stephanie R. McKeown, Declan J. McKenna Tags: ORIGINAL ARTICLE Source Type: research